ClinicalTrials.gov
ClinicalTrials.gov Menu

PIcc Cost EffectiveneSS and Safety of Infusional Therapy (PrInCESS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03392831
Recruitment Status : Not yet recruiting
First Posted : January 8, 2018
Last Update Posted : January 8, 2018
Sponsor:
Information provided by (Responsible Party):
Hospital de Clinicas de Porto Alegre

Brief Summary:

Infusion therapy comprises the parenteral administration of solutions, through peripheral or central vascular access. Some solutions and drugs are highly irritating to the vascular endothelium and therefore cannot be administered in peripheral vessels, because increase the risk of phlebitis and/or tissue necrosis. Thus, the alternative is the central venous catheter (CVC) where the access can be by direct puncture of a central vessel or peripheral vessel puncture with progression of the catheter until central positioning, through a peripherally inserted central catheter (PICC).

We must take into account that indication, insertion, handling and maintenance must be balanced with risks, benefits and costs. The insertion and maintenance of both catheters are not free of complications. Among the most frequent are: Infection, thrombosis, lumen occlusion and accidental early removal of the catheter. This often implies in the need for new vascular access, impacting on morbidity and increased treatment costs.

The PICC has some advantages over CVC, for example: avoids repetitive punctures and consequently decreased handling/pain; a lower risk of infection; avoids the use of venous dissections; reduces the risks of pneumothorax/hemothorax; reduces the risk of infiltration, extravasation, necrosis tissue and chemical phlebitis. Further, the PICC can be used as a long-term catheter with easy handling in extra-hospital condition. All these advantages suggest that this technology offers lower cost to the health system and more benefits for patients. However, PICC is not available for use in infusion therapy in patients of the Brazilian public health system, except for neonates.

The available literature does not address cost-effectiveness studies of this technology in the international scope comparing the PICC versus CVC. And, similarly, we do not have studies conducted in Brazil to incorporate this technology into our public health system, based on its benefits and potential cost reduction.

In order to fill this gap, this study aims to test if the use of PICC in patients with infusional therapy equal or superior to 10 days (Intervention Group), will show a lower incidence in the outcomes (infection, thrombosis or mechanical complications), besides being more cost-effective when compared to the use of CVC of short stay (Control Group).


Condition or disease Intervention/treatment Phase
Thrombosis Infection Other: Peripherally inserted central catheter (PICC) Other: Central venous catheter Not Applicable

Detailed Description:

Patient recruitment: Adult and pediatric patients will be included during hospitalization in the clinical/surgical units at the Hospital de Clínicas de Porto Alegre.

Variables of registry: Clinical data (diagnosis, reason for indication of catheter, site of insertion, vessel size, pharmacological treatment); Socio-demographic (age, sex, education, income); Ultrasonography (vessel evaluation); Radiography (to ensure the correct positioning of the catheter); economic variables (costs of all inputs used).

Data collection: All variables will be recorded in an instrument developed by the authors.

Statistical analysis: Continuous variables will be described using means and standard deviations or median and range in case of asymmetric distribution of data. Categorical variables will be presented using frequency distribution. Analyses will be conducted using chi-square and t tests for independent samples. P values <0.05 will be considered statistically significant. A Statistical Package for Social Sciences v.20.0 will be used. The Cox Regression Analysis and Log-rank test will compare the groups in relation to complication-free survival.

Cost-effectiveness analysis: The cost-effectiveness analysis will be measured by the incremental cost-effectiveness ratio (ICER), showed by the difference in cost between intervention and control group, divided by the difference in their effect. It represents the average incremental cost associated with 1 additional unit of the measure of effect. The cost-effectiveness analysis will be based on the cost estimate for insertion and maintenance of the catheter, including values of the inputs used, medicines, costs with professionals, surgical environment, laboratory and imaging exams.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 624 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Prospective Randomized Open Blinded End-Point (PROBE) study
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Comparative Cost-Effectiveness and Safety of Infusional Therapy With Central Venous Catheters Versus Peripherally Inserted Central Catheters: a Randomized Clinical Trial
Estimated Study Start Date : April 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Clots

Arm Intervention/treatment
Experimental: Peripherally inserted central catheter
The peripherally inserted central catheter (PICC) with 3 to 6 French calibers, with one, two or three lumens Groshong and PowerPICC models. These calibers are dependent on the amount of lumens, which are used for single or concomitant infusions.
Other: Peripherally inserted central catheter (PICC)
The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center

Active Comparator: Central venous catheter
The central venous catheter (CVC), with a short stay of 3 to 7 French gauges with one or more lumens.
Other: Central venous catheter
The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.




Primary Outcome Measures :
  1. infectious complications [ Time Frame: up to 30 days or the end of therapy ]
    bloodstream infection

  2. thrombotic complications [ Time Frame: up to 30 days or the end of therapy ]
    radiographically-confirmed upper-extremity deep vein thrombosis

  3. mechanical complications [ Time Frame: up to 30 days or the end of therapy ]
    chest X-ray

  4. accidental removal [ Time Frame: up to 30 days or need for another catheter ]
    obstruction or accidental removal


Secondary Outcome Measures :
  1. Cost Effectiveness [ Time Frame: up to 30 days or the end of therapy ]

    reduction of the rates composite outcome of complications

    • Catheter occlusion: significant reduction of infusion flow or an impairment of blood back-flow;
    • Catheter damage, malposition and catheter migration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient above 5 years old,
  • Hospitalized,
  • With prescription of infusion therapy for 10 days or more of antibiotics, antineoplastics or other drugs with a pH lower than 5 or higher than 9 and / or osmolarity above 900 mOsm / l, parenteral nutrition or hypertonic solutions.

Exclusion Criteria:

  • Insertion of the central catheter in emergency situations.
  • Critical patient in the acute or terminal stage;
  • Chronic renal disease stage IV or V and indication of hemodialysis;
  • Pediatric patients with leukemia until the induction phase;
  • Adult patients diagnosed with acute myeloid leukemia;
  • Autologous and allogenic marrow transplantation;
  • Upper limb with anatomical alteration, presence of arteriovenous fistula, axillary emptying or previous vascular procedure;
  • Presence of skin changes in the area of the puncture, such as thrombophlebitis, dermatitis, cellulitis, burn among others;
  • Patient using crutches or devices that require exertion or support in the upper limbs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03392831


Contacts
Contact: Eneida R Rabelo da Silva +5551 33085226 eneidarabelo@gmail.com
Contact: Simone S Fantin +555133598017 sfantin@hcpa.edu.br

Sponsors and Collaborators
Hospital de Clinicas de Porto Alegre
Investigators
Study Director: Carisi A Polanczyk Federal University of Rio Grande do Sul - Faculty of Medicine
Study Director: Marco A Lumertz Saffi Hospital de Clinicas de Porto Alegre
Study Director: Jeruza L Neyeloff Hospital de Clinicas de Porto Alegre

Responsible Party: Hospital de Clinicas de Porto Alegre
ClinicalTrials.gov Identifier: NCT03392831     History of Changes
Other Study ID Numbers: 170529
First Posted: January 8, 2018    Key Record Dates
Last Update Posted: January 8, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Hospital de Clinicas de Porto Alegre:
Central Venous Catheters
Vascular Access Devices
Nursing
Cost Effectiveness
PICC

Additional relevant MeSH terms:
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases